Check for updates

CLINICAL PRACTICE ARTICLE

A Hong Kong Chinese kindred with familial hypocalciuric hypercalcaemia caused by *AP2S1* mutation [version 1; peer review: 1 approved, 2 approved with reservations]

Felix Chi Kin Wong ¹, Wai Sheung Wong², Jeffrey Sung Shing Kwok¹, Teresa Kam Chi Tsui¹, Kam Piu Lau², Michael Ho Ming Chan¹, Yuet Ping Yuen¹

¹Department of Chemical Pathology, Prince of Wales Hospital, Shatin, Hong Kong

²Department of Medicine, North District Hospital, Sheung Shui, Hong Kong

V1 First published: 09 Sep 2019, 8:1612
<https://doi.org/10.12688/f1000research.20344.1>

Latest published: 09 Sep 2019, 8:1612
<https://doi.org/10.12688/f1000research.20344.1>

Abstract

Familial hypocalciuric hypercalcaemia (FHH) is a genetic disorder of altered calcium homeostasis. Mutations in the *CASR*, *GNA11* and *AP2S1* genes have been reported to cause FHH. We report a Hong Kong Chinese kindred with FHH type 3 (FHH3) caused by mutations in *AP2S1*. The proband, a 51-year-old woman with hypercalcaemia, was initially diagnosed to have primary hyperparathyroidism but repeated parathyroidectomy failed to normalize her plasma calcium concentrations. Later, FHH was suspected and yet no mutations were identified in the *CASR* gene which causes FHH type 1 (FHH1), the most common form of FHH. Genetic testing of *AP2S1* revealed a heterozygous c.43C>T (p.Arg15Cys) mutation, confirming the diagnosis of FHH3. The elder brother and niece of the proband, who both have hypercalcaemia, were found to harbour the same mutation. To our knowledge, this is the first Chinese kindred of FHH3 reported in the English literature.

Keywords

Familial hypocalciuric hypercalcaemia type III, *AP2S1*, Hong Kong Chinese

Open Peer Review

Approval Status

	1	2	3
version 1
09 Sep 2019	view	view	view

1. **Caroline Gorvin** , University of Birmingham, Birmingham, UK
2. **Fadil M. Hannan** , University of Oxford, Oxford, UK
3. **Pascal Houillier** , Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France
Paris Descartes University, Paris, France

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Felix Chi Kin Wong (felix@cuhk.edu.hk)

Author roles: **Wong FCK:** Investigation, Writing – Original Draft Preparation, Writing – Review & Editing; **Wong WS:** Investigation; **Kwok JSS:** Investigation; **Tsui TKC:** Investigation; **Lau KP:** Investigation, Supervision; **Chan MHM:** Supervision; **Yuen YP:** Investigation, Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2019 Wong FCK *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Wong FCK, Wong WS, Kwok JSS *et al.* **A Hong Kong Chinese kindred with familial hypocalciuric hypercalcaemia caused by *AP2S1* mutation [version 1; peer review: 1 approved, 2 approved with reservations]** F1000Research 2019, 8:1612 <https://doi.org/10.12688/f1000research.20344.1>

First published: 09 Sep 2019, 8:1612 <https://doi.org/10.12688/f1000research.20344.1>

Introduction

Familial hypocalciuric hypercalcaemia (FHH) is a genetically heterogeneous, autosomal dominant disorder characterized by a lifelong increase in plasma calcium concentrations with an inappropriately low urinary calcium excretion. In FHH, there is a reduction in the calcium-sensing ability of the chief cells of the parathyroid glands as well as an increase in tubular calcium reabsorption, resulting in an elevated homeostatic set-point of plasma calcium concentration and low urinary calcium excretion. Patients with FHH are generally asymptomatic, although some may develop pancreatitis or chondrocalcinosis¹. Inactivating mutations in *CASR* was first reported in 1993 to cause FHH1, the most common form of FHH². More recently, mutations in *GNA11*³ and *AP2S1*⁴ were identified to be responsible for FHH2 and FHH3, respectively. The following case report describes a Hong Kong Chinese kindred with hypercalcaemia and molecular diagnosis of FHH3. To our knowledge, this is the first Chinese kindred of FHH3 reported in the English literature.

Case report

The proband was a 51-year-old Hong Kong Chinese woman who had an incidental finding of hypercalcaemia during hospitalization for *Vibrio parahaemolyticus* gastroenteritis. She presented with watery diarrhea, vomiting and colicky abdominal pain with dehydration. Results of laboratory tests on admission were as follows: plasma sodium 143 mmol/L (reference range [RR] 135 – 145 mmol/L), potassium 3.7 mmol/L (RR 3.5 – 5.1 mmol/L), creatinine 66 µmol/L (RR 44 – 80 µmol/L), urea 6.2 mmol/L (RR 2.7 – 6.8 mmol/L), total protein 83 g/L (RR 63 – 81 g/L) and albumin 49 g/L (RR 35 – 50 g/L). Unexpectedly, a grossly elevated plasma calcium level of

3.03 mmol/L (RR 2.10 – 2.55 mmol/L) was found. The plasma phosphate was 1.07 mmol/L (RR 0.90 – 1.55 mmol/L) and plasma alkaline phosphatase (ALP) was 97 U/L (RR 35 – 104 U/L). The patient had a past history of multi-nodular goiter and uterine fibroids with total hysterectomy and salpingo-oophorectomy performed in 1999. She did not have symptoms suggestive of hypercalcaemia, primary hyperparathyroidism or urolithiasis. She never took any calcium or vitamin supplements, and was not on any regular or over-the-counter medications.

After rehydration, the plasma calcium was persistently elevated at 2.79 mmol/L. Whole blood ionized calcium was elevated at 1.47 mmol/L (RR 1.13 – 1.32 mmol/L), confirming genuine hypercalcaemia. The paired plasma parathyroid hormone (PTH) level was inappropriately normal (6.9 pmol/L, RR 1.7 – 9.2 pmol/L). Urinary calcium excretion over 24 hours was normal at 3.26 mmol/day (RR 2.50 – 8.00 mmol/day) with a urine volume of 2.23 L. Spot urine calcium and creatinine concentrations were also measured one day before the aforementioned 24-hour urine collection with paired measurement of plasma calcium and creatinine concentrations. The fractional excretion of calcium (FECa) was not documented in the patient's medical record. In retrospect, it was low (0.55%, see Table 1, six months after presentation). Blood for serum protein electrophoresis, immunoglobulin pattern, erythrocyte sedimentation rate (ESR), and chest X-ray were unremarkable. Ultrasonography showed multi-nodular disease of thyroid gland and no parathyroid mass. Technetium-99m sestamibi parathyroid scintigraphy showed a small extra-thyroidal uptake focus near the lower pole of the right thyroid lobe suggestive of a right inferior parathyroid adenoma. A diagnosis

Table 1. Summary of the biochemical findings of all affected family members. Biochemical results measured on the same day are tabulated on the same row. The FECa of all affected family members was consistently below 1% (**bold**). *Age at which the patient first presented with hypercalcaemia. †Calculation of the fractional excretion of calcium (FECa) is as follows: $[(\text{urine calcium}) \times (\text{plasma creatinine})] / [(\text{urine creatinine}) \times (\text{plasma calcium})] \times 100\%$. ‡During the episode of acute pancreatitis. Reference ranges: plasma calcium (2.10 – 2.55 mmol/L), plasma phosphate (0.90 – 1.55 mmol/L), plasma creatinine (44 – 80 µmol/L), plasma PTH (1.7 – 9.2 pmol/L). Abbreviations: Ca, calcium; Cr, creatinine; FECa, fractional excretion of calcium; PO₄, phosphate.

Patient No.	Age (years)*	Time of measurement	Plasma Ca (mmol/L)	Plasma PO ₄ (mmol/L)	Plasma Cr (µmol/L)	Type of urine specimen	Urine Ca (mmol/L)	Urine Cr (mmol/L)	FECa (%)†	Plasma PTH (pmol/L)
II(4) (proband)	51	At presentation	3.03	1.07	66	--	--	--	--	6.9
		Six months later	2.84	1.01	58	Spot	0.91	3.4	0.55	--
		2 years later	2.63	1.10	56	24 hour	0.62	1.9	0.69	--
II(1)	54	At presentation	2.80	0.71	57	--	--	--	--	3.2
		5 years later	2.89	0.94	68	Spot	4.43	12.6	0.83	--
III(1)	29	At presentation	2.69	0.40	54	--	--	--	--	5.1
		2 years later‡	2.65	0.95	42	--	--	--	--	1.5
		2 years and 2 days later‡	2.69	0.99	39	Spot	0.3	4.9	0.09	--
		3 years later	2.66	0.92	61	Spot	0.9	11.5	0.15	--
		7 years later	2.60	--	50	Spot	3.47	8.9	0.75	--

of primary hyperparathyroidism due to right inferior parathyroid adenoma was made.

Right inferior parathyroidectomy was performed 2 years after initial presentation. A $1 \times 0.5 \times 0.3$ cm ovoid nodule was excised and frozen section showed a piece of parathyroid tissue without evidence of malignancy. However, the patient had persistent hypercalcaemia postoperatively with a plasma PTH level of 5.5 pmol/L. In addition, the surgical site was complicated by local haematoma formation. A second operation for haemostasis and subtotal parathyroidectomy was performed three days after the first operation. In order to maximize the probability of excising any hyperactive parathyroid tissue so that the normalization of plasma calcium level may be achieved, the right superior parathyroid gland and left inferior parathyroid gland were also excised, leaving only the left superior parathyroid gland in place. Histological examination confirmed further removal of parathyroid tissue with no evidence of parathyroid neoplasm. Nevertheless, her plasma calcium level remained elevated at levels of 2.63 to 2.84 mmol/L while the plasma PTH level remained non-suppressed at 4.6 pmol/L after the second operation. Technetium-99m sestamibi parathyroid scintigraphy three months after the second operation showed a suspicious right inferior hyperfunctioning parathyroid lesion, raising the possibility of residual parathyroid disease.

After failing parathyroidectomy twice, the patient realized for the first time that her elder brother and her elder brother's daughter also had incidental findings of hypercalcaemia (See Figure 1 for the pedigree and Table 1 for the summary of biochemical results). Upon further evaluation of the proband, 24-hour urine collection was repeated revealing a low urinary calcium excretion [2.09 mmol/day, urine volume 3.37 L, (RR 2.50 – 8.00 mmol/day)]. Spot urine calcium was 0.62 mmol/L and spot urine creatinine was 1.9 mmol/L. The concomitant plasma calcium was 2.63 mmol/L and plasma

creatinine was 56 μ mol/L. The FECa was 0.69%. A FECa of less than 1% is compatible with a diagnosis of FHH.

The elder brother of the proband presented at the age of 54 years with an incidental finding of hypercalcaemia (plasma calcium: 2.80 mmol/L) during hospitalization for an episode of syncope. Measurement of 24-hour urinary calcium excretion was not performed. FECa was 0.83%. The niece of the proband presented at the age of 29 years with an incidental finding of hypercalcaemia (plasma calcium: 2.69 mmol/L) during hospitalization for urinary tract infection. Two years later, she had an episode of acute pancreatitis during pregnancy at 37 weeks' gestation with serum amylase up to 1377 U/L. The concomitant triglyceride level was 1.7 mmol/L (RR <1.7 mmol/L) and plasma calcium was 2.65 – 2.69 mmol/L. Emergency Caesarean section was performed with uneventful delivery of a healthy baby boy, although the calcium status of her baby was unknown. Her pancreatitis responded to conservative management. Ultrasound of the neck showed no parathyroid nodules. Urinary calcium excretion over 24 hours was measured on two occasions but both results were within normal limits (4.92 and 3.18 mmol/day collected three years apart, with urine volumes of 3.3 and 3.5 L/day respectively). FECa was persistently low (0.09 – 0.75%).

Mutation analysis of the calcium-sensing receptor (*CASR*) gene was performed for the proband with all coding exons and flanking introns sequenced in both directions. No known pathogenic variants were identified. As a result, a diagnosis of FHH type 1 could not be confirmed. Sanger sequencing of the adaptor-related protein complex 2, sigma-1 subunit (*AP2S1*) gene showed heterozygous *AP2S1* NM_004069.3: c.43C>T (p.Arg15Cys), which is a known pathogenic mutation of FHH3. The same *AP2S1* mutation was identified in both her elder brother and niece, confirming the diagnosis of FHH3 in all three individuals. All three patients appeared to be cognitively

Figure 1. The pedigree of this family was compatible with autosomal dominant inheritance of hypercalcaemia. The proband is indicated by an arrow. The phenotype (plasma calcium concentration) as well as genotype of both parents of the proband is unknown. The plasma calcium concentration of the son of the proband [III(2)] was normal and targeted *AP2S1* mutation analysis was negative. The calcium status of the baby boy of III(1) was not available and it was omitted from the pedigree.

normal. They were followed up for the monitoring of plasma calcium concentration. Up to one year after the genetic diagnosis was made, they remained asymptomatic and no treatment was given.

Discussion

FHH is an important differential diagnosis of hypercalcaemia that one must carefully differentiate from primary hyperparathyroidism. The most indicative biochemical parameter for the diagnosis of FHH is the fractional excretion of calcium (FECa), also known as urinary calcium to creatinine clearance ratio. It is typically less than 1% in patients with FHH⁵⁻⁷. As exemplified in this case report, the diagnosis of FHH could be missed if 24-hour urinary calcium excretion only is taken into consideration. For calculation of the FECa, a spot urine sample or a 24-hour urine sample may be used, although 24-hour urine samples were originally employed to derive the cut offs^{5,6}. Plasma PTH levels may be normal or raised in patients with FHH, similar to patients with primary hyperparathyroidism. Frequently, it remains difficult to distinguish primary hyperparathyroidism and FHH based on the available clinical, biochemical and radiological evidence, and the definitive diagnosis of FHH could only be achieved by genetic testing. Approximately 65% of individuals with FHH has FHH1, which is the most common type of FHH due to a loss-of-function of the calcium-sensing receptor (CaSR)⁸. More recently, mutations in *GNA11* and *AP2S1* have been identified to cause FHH2 and FHH3, respectively. FHH3 is caused by mutations at the Arg15 residue of the AP2S1 protein. Three different amino acid substitutions have been identified at this arginine residue, namely p.Arg15Cys (CGC→TGC), p.Arg15Leu (CGC→CTC) and p.Arg15His (CGC→CAC). The Arg15 residue is highly evolutionarily conserved. *In vitro* functional studies suggest that a replacement of the positively charged Arg15 residue with the polar, but uncharged, Cys15 residue compromises the function of the adaptor-related protein complex 2 by reducing its affinity for the C-terminal calcium sensing receptor (CaSR) dileucine motifs, affecting the sensitivity of CaSR-expressing

cells to extracellular calcium as well as resulting in the reduction of CaSR endocytosis⁴. In the same study, 11 individuals were found to harbour FHH3 mutations in 50 unrelated individuals with *CASR* mutation-negative FHH. Therefore, it is likely that *AP2S1* mutations may be found in approximately 20% of patients of FHH without *CASR* mutations⁴. FHH2 is much rarer than FHH1 or FHH3. In fact, not a single case of FHH2 was detected in studies which collectively involved more than 200 patients with a phenotype of FHH⁹⁻¹¹. Compared with patients with FHH1, patients with FHH3 are more likely to have higher serum calcium and magnesium, and lower fractional excretion of calcium. In addition, cognitive dysfunction, such as learning disability and attention deficit hyperactivity disorder, was seen in some patients with FHH3 and this was not seen in patients with FHH1^{11,12}. No apparent cognitive dysfunction was seen in any of our patients, and magnesium levels were not checked. Cinacalcet, a licensed calcium-sensing receptor allosteric activator, has been used successfully to reduce plasma calcium levels and hypercalcaemic symptoms in symptomatic FHH3 patients¹³. One of our patients (Figure 1, [III(1)]) developed an episode of acute pancreatitis during pregnancy, with no recurrence afterwards. Otherwise, they were free of hypercalcaemic complications or symptoms, and therefore no treatment was given.

In summary, we have reported the first Chinese kindred with FHH3 in the English literature. Mutation analysis of *AP2S1* should be performed when the diagnosis of FHH is highly likely and yet no mutations in the *CASR* gene could be identified.

Consent

Written informed consent for publication of their clinical details was obtained from all three patients.

Data availability

Underlying data

All data underlying the results are available as part of the article and no additional source data are required.

References

- Thakker RV: **Diseases associated with the extracellular calcium-sensing receptor.** *Cell Calcium*. 2004; 35(3): 275–282.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Pollak MR, Brown EM, Chou YH, et al.: **Mutations in the human Ca²⁺-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism.** *Cell*. 1993; 75(7): 1297–1303.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Nesbit MA, Hannan FM, Howles SA, et al.: **Mutations affecting G-protein subunit α_1 in hypercalcemia and hypocalcemia.** *N Engl J Med*. 2013; 368(26): 2476–2486.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Nesbit MA, Hannan FM, Howles SA, et al.: **Mutations in *AP2S1* cause familial hypocalciuric hypercalcemia type 3.** *Nat Genet*. 2013; 45(1): 93–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Marx SJ, Attie MF, Levine MA, et al.: **The hypocalciuric or benign variant of familial hypercalcemia: clinical and biochemical features in fifteen kindreds.** *Medicine (Baltimore)*. 1981; 60(6): 397–412.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Law WM Jr, Heath H 3rd: **Familial benign hypercalcemia (hypocalciuric hypercalcemia). Clinical and pathogenetic studies in 21 families.** *Ann Intern Med*. 1985; 102(4): 511–519.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Brown EM: **Clinical lessons from the calcium-sensing receptor.** *Nat Clin Pract Endocrinol Metab*. 2007; 3(2): 122–133.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Nesbit MA, Hannan FM, Graham U, et al.: **Identification of a second kindred with familial hypocalciuric hypercalcemia type 3 (FHH3) narrows localization to a <3.5 megabase pair region on chromosome 19q13.3.** *J Clin Endocrinol Metab*. 2010; 95(4): 1947–1954.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hovden S, Rejnmark L, Ladefoged SA, et al.: ***AP2S1* and *GNA11* mutations - not a common cause of familial hypocalciuric hypercalcemia.** *Eur J Endocrinol*. 2017; 176(2): 177–185.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Vargas-Poussou R, Mansour-Hendili L, Baron S, et al.: **Familial Hypocalciuric Hypercalcemia Types 1 and 3 and Primary Hyperparathyroidism: Similarities and Differences.** *J Clin Endocrinol Metab*. 2016; 101(5): 2185–2195.
[PubMed Abstract](#) | [Publisher Full Text](#)

11. Szalat A, Shpitzen S, Tsur A, *et al.*: **Stepwise *CaSR*, *AP2S1*, and *GNA11* sequencing in patients with suspected familial hypocalciuric hypercalcemia.** *Endocrine*. 2017; 55(3): 741–747.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Hannan FM, Howles SA, Rogers A, *et al.*: **Adaptor protein-2 sigma subunit mutations causing familial hypocalciuric hypercalcaemia type 3 (FHH3) demonstrate genotype-phenotype correlations, codon bias and dominant-negative effects.** *Hum Mol Genet*. 2015; 24(18): 5079–5092.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Howles SA, Hannan FM, Babinsky VN, *et al.*: **Cinacalcet for Symptomatic Hypercalcemia Caused by *AP2S1* Mutations.** *N Engl J Med*. 2016; 374(14): 1396–1398.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 01 November 2019

<https://doi.org/10.5256/f1000research.22357.r55718>

© 2019 Houillier P. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Pascal Houillier

¹ Department of Physiology, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France

² Paris Descartes University, Paris, France

Wong *et al* describe a Chinese kindred with FHH 3 due to a monoallelic point mutation in the AP2S1 gene. The phenotype of the proband and affected relatives is well described and the report is well written. I have a few comments that I submit to the consideration of the authors:

- The work-up of patients with primary hyperparathyroidism commonly includes renal ultrasonography (or CT scan) and bone mineral density measurement. Was any of those performed in any of the patients? If so, the results should be provided. If not, this should be mentioned.
- A score, named Pro-FHH,¹ has recently been reported as performing better than CCCR to distinguish patients with primary hyperparathyroidism and with FHH. Could Pro-FHH be retrospectively be computed in the patients? The respective merits of CCCR and Pro-FHH could be discussed.
- The description of the parathyroid tissue is a bit confusing. Is neoplasm used instead of carcinoma? Was the removed parathyroid tissue totally normal (on a quantitative and qualitative basis), or hyperplastic or anything?
- Table 1 should be cited when describing the biochemistry in the brother and the niece.
- Hospitalization for urinary tract infection is uncommon unless it is complicated. Was it?
- The risk of post surgical hypoparathyroidism after repeated parathyroid surgery should be mentioned in the discussion.
- page 1, introduction: renal tubular calcium reabsorption

References

1. Bertocchio J, Tafflet M, Koumakis E, Maruani G, et al.: Pro-FHH: A Risk Equation to Facilitate the Diagnosis of Parathyroid-Related Hypercalcemia. *The Journal of Clinical Endocrinology & Metabolism*. 2018; **103** (7): 2534-2542 [Publisher Full Text](#)

Is the background of the cases' history and progression described in sufficient detail?

Yes

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?

Partly

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?

Partly

Is the conclusion balanced and justified on the basis of the findings?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Disorders of mineral homeostasis

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 21 October 2019

<https://doi.org/10.5256/f1000research.22357.r54582>

© 2019 Hannan F. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Fadil M. Hannan

Academic Endocrine Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, UK

The Clinical Practice Article by Wong and colleagues describes the first report of a Chinese kindred with familial hypocalciuric hypercalcaemia type 3 (FHH3). It is informative and well written, and provides detailed phenotypic information for this kindred. I have a few comments, which require addressing:

Title:

- Please insert details of the mutation e.g. "...hypercalcaemia caused by an AP2S1 mutation, Arg15Cys"

Page 3:

- In the paragraph detailing parathyroid histology in the proband, is the term 'without evidence of malignancy', referring to parathyroid adenoma or carcinoma? Malignancy should not be used interchangeably with parathyroid adenoma, given that this is a benign condition.
- Please avoid the term 'parathyroid neoplasm' as this suggests that histology is being undertaken to assess for parathyroid carcinoma.
- Please cite Table 1 in the paragraph describing the findings in the elder brother.
- Table 1 should be cited after the statement 'FECa was 0.83%'.
- Also cite Table 1 when describing the niece's biochemistry.
- Please state if gallstones were excluded as a cause of the acute pancreatitis

Page 4:

- This article would benefit from a more in depth discussion of the pancreatitis in the niece. The authors should mention that pancreatitis has previously been reported in a child with FHH3 (Scheers et al Pancreatology 2019). This reported patient also harboured a mutation in the SPINK1 gene, which represents a risk factor for pancreatitis. The authors should indicate whether or not the niece has been tested for a mutation in the SPINK1 gene.

Table 1:

- Please insert serum 25-hydroxyvitamin D values for members of this kindred.

Figure 1:

- Please insert sequence trace for the proband showing the c.43C>T nucleotide substitution in the AP2S1 gene.

Is the background of the cases' history and progression described in sufficient detail?

Yes

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?

Partly

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?

Partly

Is the conclusion balanced and justified on the basis of the findings?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Genetics of calcium and parathyroid disorders, molecular endocrinology of lactation

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 16 October 2019

<https://doi.org/10.5256/f1000research.22357.r54581>

© 2019 Gorvin C. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Caroline Gorvin

Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK

Wong *et al* describe a Chinese kindred with FHH in which they have identified a previously described mutation in *AP2S1*. This is a comprehensive case report with detailed descriptions of the proband and several family members. Whilst not novel, this report describes FHH3 in a new ethnic population and further demonstrates that mutations in the Arg15 residue are the most commonly identified in FHH3. I have recommended some minor edits to improve the clarity of the report that are outlined below.

1. At present there are very few references in the introduction. Perhaps a few more could be inserted.
2. Please add an asterisk (or other appropriate symbol) next to statistically significant values in Table 1. This will make it immediately clear to the reader which values are significant.
3. The statement about FECa being <1% in FHH is made on page 3. This should be brought forward to page 2 following the first statement about the proband's FeCa.
4. The second paragraph of page 2 begins with a statement about other members of the proband's family, then goes on to discuss the proband again. I think this statement should be moved down to just before the mutational analysis. It will make the case report easier for a reader to understand if the proband is discussed first, then other family members later.

Is the background of the cases' history and progression described in sufficient detail?

Yes

Are enough details provided of any physical examination and diagnostic tests, treatment

given and outcomes?

Yes

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?

Yes

Is the conclusion balanced and justified on the basis of the findings?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Calcium-sensing receptor, Hyper/Hypocalcaemia, GPCRs, Cell signalling

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research